 |
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2016, vol. 22, issue 3
Subject Area: Medicine
Pages: 1314-1319
DOI: 10.5272/jimab.2016223.1314
Published online: 27 September 2016
J of IMAB 2016 Jul-Sep;22(3):1314-1319
CORRELATION BETWEEN SERUM TESTOSTERONE, BIOCHEMICAL AND CLINICAL MARKERS IN PROSTATE CANCER PATIENTS
Bogdan Roussev1 
, Petar Kosev2, Alexander Hinev3, Bistra Galunska1,
1) Department of Biochemistry, Molecular Medicine and Nutrigenomics, Medical University - Varna, Bulgaria
2) Urology Clinic, University Hospital “St. Marina”, Varna, Bulgaria
3) Department of Urology, Medical University – Varna, Bulgaria.
ABSTRACT:
Purpose: Androgens seems to play an important role in prostate cancer (PCa) pathogenesis. Some studies reveal that possible testosterone deficiency could be involved in PCa development and progress. Others indicate that men with high testosterone levels have increased risk in developing more aggressive PCa and poor response to therapy. The objective of the present study is to establish a possible correlation between serum total testosterone levels (TT), prostate specific antigen (PSA) and clinical markers evaluating the aggressiveness of the tumor process in PCa patients.
Material/Methods: A total of eighty males, aged from 52 to 84 years (mean age 66.28 ± 6.015 years), with histologically confirmed PCa, entered the study. Diagnosis of PCa was established by systemic transrectal ultrasound-guided tru-cut prostate biopsies (10 cores at least). Detected tumors were graded using the Gleason grading system. Serum TT and PSA were analyzed immunochemically. Pearson correlation statistics with a level of significance set at p < 0.05 was used for data analysis.
Results: Strong significant positive correlation (Pearson r=0.90, p<0.01) between PSA and testosterone levels was found in lowest risk group. For the highest risk group there was a negative association between the same parameters (Pearson r=-0.38, p<0.05). A relatively weak positive relationship (Pearson r = 0.29) was detected for patients with less aggressive tumors (Gleason score <7) and a negative trend (Pearson r = -0.27) in patients with highly aggressive prostate cancer (Gleason >7).
Conclusions: Our results confirm the hypothesis that low testosterone levels are related to poor prognosis and increased severity of PCa.
Key words: Testosterone, Prostate cancer, PSA, Gleason,
- Download FULL TEXT /PDF 808 KB/
Please cite this article in PubMed Style or AMA (American Medical Association) Style:
Roussev B, Kosev P, Hinev A, Galunska B. Correlation between serum testosterone, biochemical and clinical markers in prostate cancer patients. J of IMAB. 2016 Jul-Sep;22(3):1314-1319.
DOI: http://dx.doi.org/10.5272/jimab.2016223.1314.
Correspondence to: Bogdan Roussev, Department of Biochemistry, Molecular Medicine and Nutrigenomics, Medical University – Varna; 84, Tsar Osvoboditel Str., 9002 Varna, Bulgaria; E-mail: bogdanroussev@gmail.com
REFERENCES:
1. Michaud JE, Billups KL, Partin AW. Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk. Ther Adv Urol. 2015 Dec;7(6):378-87. [PubMed]
2. Basaria S. Male hypogonadism. Lancet. 2014; Apr;383(9934):1250-1263. [PubMed]
3. Waltregny D, Leav I, Signoretti S, Soung P, Lin D, Merk F, et al. Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol Endocrinol. 2001; May;15(5):765-82. [PubMed]
4. Davey R, Grossmann M. Androgen Receptor Structure, Function and Biology: From Bench to Bedside. Clin Biochem Rev. 2016; Feb; 37(1): 3–15. [PubMed]
5. Xiaohui Xu, Xinguang Ch, Hui Hu, Dailey B, Taylor D. Current opinion on the role of testosterone in the development of prostate cancer: a dynamic model. BMC Cancer. 2015 Oct;15:806. [PubMed]
6. Ahmad I, Sansom O, Leung H. Advances in mouse models of prostate cancer. Expert Rev Mol Med. 2008 Jun 9;10:e16. [PubMed]
7. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol. 2000 Feb;18(4):847-53. [PubMed]
8. Rove KO, Crawford ED. Traditional androgen ablation approaches to advanced prostate cancer: new insights. Can J Urol. 2014 Apr;21(2 Supp 1):14-21. [PubMed]
9. Klap J, Schmid M, Loughlin KR. The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy. J Urol. 2015 Feb;193(2):403-13. [PubMed]
10. Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology. 2006 Dec;68(6):1263-7. [PubMed]
11. Shin BS, Hwang EC, Im CM, Kim SO, Jung SI, Kang TW, et al. Is a decreased serum testosterone level a risk factor for prostate cancer? A cohort study of korean men. Korean J Urol. 2010 Dec;51(12):819-23. [PubMed]
12. Roddam AW, Allen NE, Appleby P, Key TJ, EHPCCG. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008 Feb 6;100(3):170-83. [PubMed]
13. Isbarn H, Pinthus JH, Marks LS, Montorsi F, Morales A, Morgentaler A, et al. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol. 2009 Jul;56(1):48-56. [CrossRef]
14. Dai B, Qu Y, Kong Y, Ye D., Yao X., Zhang S. et al. Low pretreatment serum total testosterone is associated with a high incidence of Gleason score 8–10 disease in prostatectomy specimens: data from ethnic Chinese patients with localized prostate cancer. BJU Int. 2012 Dec;110(11 Pt B):E667-E672. [PubMed]
15. Xylinas E, Ploussard G, Durand X, Fabre A, Salomon L, Allory Y, et al. Low pretreatment total testosterone (<3 ng/ml) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancer. BJU Int. 2011 May;107(9):1400-1403. [PubMed]
16. Albisinni S, De Nunzio C, Tubaro A, Barry WT, Banez LL, Freedland SJ. Greater percent-free testosterone is associated with high-grade prostate cancer in men undergoing prostate biopsy. Urology. 2012 Jul;80(1):162-7. [PubMed]
17. European Association of Urology (EAU). Oncological guidelines-prostate cancer-full text-classification & staging systems. [Internet]
18. Garcнa-Cruz E, Piqueras M, Huguet J, Peri L, Izquierdo L, Musquera M, et al. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment. BJU Int. 2012 Dec;110(11 Pt B):E541-6. [PubMed]
19. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol. 2006 Nov;50(5):935-9. [PubMed]
20. Rhoden EL, Riedner CE, Morgentaler A. The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men. J Urol 2008 May;179(5):1741-4. [PubMed]
21. Khera M, Crawford D, Morales A, Salonia A, Morgentaler A. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol. 2014 Jan;65(1):115-23. [PubMed]
22. Salonia A, Abdollah F, Capitanio U, Suardi N, Briganti A, Gallina A, et al. Serum sex steroids depict a nonlinear u-shaped association with high-risk prostate cancer at radical prostatectomy. Clin Cancer Res. 2012 Jul 1;18(13):3648-57. [PubMed]
23. Morgentaler A 3rd, Conners WP. Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations. Asian J Androl. 2015 Mar-Apr;17(2):206-11. [PubMed]
24. Kampa M, Papakonstanti EA, Hatzoglou A, Stathopoulos EN, Stournaras C, Castanas E. The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors that increase PSA secretion and modify actin cytoskeleton. FASEB J. 2002 Sep;16(11):1429-31. [PubMed]
25. Rove KO, Debruyne FM, Djavan B, Gomella LG, Koul HK, Lucia MS, et al. Role of testosterone in managing advanced prostate cancer. Urology. 2012 Oct;80(4):754-62. [PubMed]
26. Kim HJ, Kim BH, Park CH, Kim CI. Usefulness of preoperative serum testosterone as a predictor of extraprostatic extension and biochemical recurrence. Korean J Urol. 2012 Jan;53(1):9-13. [PubMed]
27. Salonia A, Abdollah F, Capitanio U, Gallina A, Suardi N, Briganti A, et al. Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy. World J Urol. 2013 Apr;31(2):275-80. [PubMed]
28. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009 Feb;55(2):310-20. [PubMed]
29. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996 Aug 21;88(16):1118-26. [PubMed]
30. Wang WL, Tenniswood M. Vitamin D, intermediary metabolism and prostate cancer tumor progression. Front Physiol. 2014 May 15;5:183. [PubMed]
31. Eisenberg ML. Testosterone Replacement Therapy and Prostate Cancer Incidence. World J Mens Health. 2015 Dec;33(3):125-9. [PubMed].
Received: 14 June 2016
Published online: 27 September 2016